etoricoxib 120 mg
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Laparoscopic Surgery for Appendicitis
Conditions
Laparoscopic Surgery for Appendicitis, Laparoscopic Surgery for Cholecystitis, Laparoscopic Surgery for Ovarian Cysts
Trial Timeline
Apr 1, 2006 → Dec 1, 2006
NCT ID
NCT00565682About etoricoxib 120 mg
etoricoxib 120 mg is a approved stage product being developed by Merck for Laparoscopic Surgery for Appendicitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00565682. Target conditions include Laparoscopic Surgery for Appendicitis, Laparoscopic Surgery for Cholecystitis, Laparoscopic Surgery for Ovarian Cysts.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00565682 | Approved | Completed |
Competing Products
7 competing products in Laparoscopic Surgery for Appendicitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pudexacianinium chloride | Astellas Pharma | Phase 2 | 52 |
| SHR0410 Injection + SHR0410 Injection + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Entereg + Entereg + placebo | Merck | Phase 2 | 52 |
| Rocuronium + Rocuronium | Merck | Approved | 85 |
| Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2 | Merck | Approved | 85 |
| placebo + valdecoxib + valdecoxib | Pfizer | Phase 3 | 76 |
| N1539 + N1539 + N1539 + Ketorolac Tromethamine + Placebo | Alkermes | Phase 3 | 74 |